当代1型糖尿病大型队列中肾脏疾病进展的预测
研究基于苏格兰5777例成人1型糖尿病队列,中位年龄44.1岁、糖尿病病程20.9年。CKD G3-G5期患者中59%无白蛋白尿,ESRD发病率为2.5/1000人年。中位eGFR年下降仅-1.3 ml min-1 [1.73 m]-2,但14%下降≥3 ml min-1 [1.73 m]-2,预测仍具挑战。
要点
- 当代1型糖尿病CKD患病率低于历史估计,但ESRD仍达2.5/1000人年。
- 多数CKD G3-G5期患者无白蛋白尿,仅凭白蛋白尿筛查可能漏诊。
- 14%患者eGFR年下降≥3 ml min-1 [1.73 m]-2,与心血管疾病和视网膜病变相关。
核心结论
- 当代1型糖尿病队列肾脏疾病水平低于历史估计,但早期识别eGFR显著下降者仍困难。
研究设计与样本
- 基于苏格兰糖尿病研究网络1型生物资源库(SDRNT1BIO)的5777例16岁以上、50岁前诊断的1型糖尿病成人队列。
- 测量基线血清肌酐和尿白蛋白/肌酐比值(ACR),链接国家电子健康记录进行观察。
主要发现
- CKD G1、G2、G3、G4期和ESRD患病率分别为64.0%、29.3%、5.4%、0.6%、0.7%。
- 微量白蛋白尿和大量白蛋白尿患病率分别为8.6%和3.0%。
- ESRD发病率为2.5(95% CI 1.9, 3.2)/1000人年。
- CKD G3-G5期患者中59%在招募当日或既往无白蛋白尿。
- 中位eGFR年下降-1.3 ml min-1 [1.73 m]-2(IQR:-2.2, -0.4),14%下降≥3 ml min-1 [1.73 m]-2。
临床怎么用
- 在1型糖尿病中应关注eGFR轨迹而非仅依赖白蛋白尿来评估肾脏风险。
- 合并心血管疾病或视网膜病变者eGFR下降风险更高,需加强监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to provide data from a contemporary population-representative cohort on rates and predictors of renal decline in type 1 diabetes. METHODS: We used data from a cohort of 5777 people with type 1 diabetes aged 16 and older, diagnosed before the age of 50, and representative of the adult population with type 1 diabetes in Scotland (Scottish Diabetes Research Network Type 1 Bioresource; SDRNT1BIO). We measured serum creatinine and urinary albumin/creatinine ratio (ACR) at recruitment and linked the data to the national electronic healthcare records. RESULTS: Median age was 44.1 years and diabetes duration 20.9 years. The prevalence of CKD stages G1, G2, G3 and G4 and end-stage renal disease (ESRD) was 64.0%, 29.3%, 5.4%, 0.6%, 0.7%, respectively. Micro/macroalbuminuria prevalence was 8.6% and 3.0%, respectively. The incidence rate of ESRD was 2.5 (95% CI 1.9, 3.2) per 1000 person-years. The majority (59%) of those with chronic kidney disease stages G3-G5 did not have albuminuria on the day of recruitment or previously. Over 11.6 years of observation, the median annual decline in eGFR was modest at -1.3 ml min-1 [1.73 m]-2 year-1 (interquartile range [IQR]: -2.2, -0.4). However, 14% experienced a more significant loss of at least 3 ml min-1 [1.73 m]-2. These decliners had more cardiovascular disease (OR 1.9, p = 5 × 10-5) and retinopathy (OR 1.3 p = 0.02). Adding HbA1c, prior cardiovascular disease, recent mean eGFR and prior trajectory of eGFR to a model with age, sex, diabetes duration, current eGFR and ACR maximised the prediction of final eGFR (r2 increment from 0.698 to 0.745, p < 10-16). Attempting to model nonlinearity in eGFR decline or to detect latent classes of decliners did not improve prediction. CONCLUSIONS: These data show much lower levels of kidney disease than historical estimates. However, early identification of those destined to experience significant decline in eGFR remains challenging.
引用
- Colombo M, McGurnaghan SJ, Bell S, et al. Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia. 2019. PMID: 31807796. doi:10.1007/s00125-019-05052-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。